Acumen Q3 2024 Earnings Report
Key Takeaways
Acumen Pharmaceuticals reported a net loss of $29.8 million for the third quarter of 2024. As of September 30, 2024, cash, cash equivalents and marketable securities totaled $258.9 million, which is expected to support current clinical and operational activities into the first half of 2027.
ALTITUDE-AD Phase 2 study enrollment expected to complete in the first half of 2025.
Topline results of Phase 1 study for subcutaneous administration of sabirnetug expected in the first quarter of 2025.
Cash, cash equivalents and marketable securities totaled $258.9 million as of Sept. 30, 2024.
Cash is expected to support current clinical and operational activities into the first half of 2027.
Acumen
Acumen
Forward Guidance
Acumen expects ALTITUDE-AD, a Phase 2 study to investigate sabirnetug for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025 and expects to announce topline results of a Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025.